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Plasma macrophage-derived chemokine (CCL22) and its receptor CCR4 
on peripheral blood T lymphocytes of asthmatic children  
INTRODUCTION 
Chemokines and chemokine receptors provide 
directional cues for leukocyte migration and 
concomitantly induce the recruitment of T cells into 
the sites of inflammation. This process is 
particularly important in atopic diseases such as 
bronchial asthma. Initial studies in this area have 
emphasized that chemokine receptor expression is 
tightly regulated on TH cells, and that TH cell 
subsets express restricted chemokine receptors. For 
example, TH1 cells express the chemokine 
receptors CXCR3 and CCR5, while CCR4, CCR8, 
and CCR9 are found on TH2 cells.1, 2  
CCR4 is a receptor that binds 2 chemokines; 
CCL17/TARC (Thymus and Activation-Regulated 
Chemokine), and CCL22/MDC (Macrophage-
Derived Chemokine). The receptor was originally 
isolated from a basophilic cell line and shown to be 
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Background: The macrophage-derived chemokine (MDC/CCL22) acts on 
CC chemokine receptor-4 (CCR4) to direct trafficking and recruitment of T 
helper-2 (TH2) cells into sites of allergic inflammation. It was previously 
found overexpressed in lesional samples from adult asthmatics.  
 Objective: This study is aimed to investigate the participation of 
CCR4/MDC axis in the development of TH2-dominated allergen-induced 
childhood asthma in relation to disease activity, attack severity, and 
response to therapy, and to outline its value in differentiating atopic asthma 
from infection-associated airway reactivity. 
Methods: Proportion of CCR4-expressing peripheral blood T lymphocytes 
(CCR4+PBTL%) were purified and quantitated by negative selection from 
peripheral blood mononuclear cells by flow cytometry, and the 
concentration of MDC in plasma was measured by ELISA in 32 children 
with atopic asthma (during exacerbation and remission), as well as in 12 
children with acute lower respiratory tract infections (ALRTI), and 20 
healthy children serving as controls. 
Results: The mean plasma MDC level (925±471.5 pg/ml) and 
CCR4+PBTL% (55.3±23.6%) were significantly higher in asthmatic children 
during acute attacks in comparison to children with ALRTI (109±27.3 pg/ml 
and 27.6±7.5%) and healthy controls (99.6±25.6 pg/ml and 24.2±4.1%). 
Both values decreased significantly after subsidence of attacks (502±284.3 
pg/ml and 32.5±10.5%) although remained higher than the other 2 groups 
which were actually comparable in terms of MDC and CCR4%. MDC and 
CCR4% values were higher among children with acute severe than mild or 
moderate asthma exacerbations, and in persistent than intermittent cases 
during stability. Positive correlations could be elicited between both 
markers during exacerbation or stability, and between the exacerbation level 
of each and its corresponding value during remission. Corticosteroid-
treated patients had the highest expression of both markers when relation to 
therapy was studied.  
Conclusion: Our findings reinforce the concept that up regulation of 
CCR4/MDC axis is implicated in the pathogenesis of pediatric atopic 
asthma and may represent a useful biomarker of monitoring allergic 
inflammation and response to therapy. Neutralization and manipulation of 
CCR4-expressing T cells, as well as MDC antagonism, may represent an 
adjuvant in the treatment of severe allergic disorders.  
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expressed on a subpopulation of peripheral blood 
lymphocytes, thymocytes, mature dendritic cells 
and recently on blood platelets.3 Current evidence 
suggests that CCR4 expression is associated with 
TH-2 responses. Activation of T cells through their 
T-cell receptor can induce elevated CCR4 levels, 
which can last up to two days.4  
Chemokines basically have been divided into 
two main families, CXC and CC chemokines, based 
on the sequence homology and the position of the 
first two cysteine residues. CXC chemokines are 
typically chemotactic for neutrophils, whereas CC 
chemokines attract and activate monocytes and 
lymphocytes.5 MDC or CCL22 is a novel human 8 
kDa CC chemokine. It was originally cloned from 
human monocyte-derived macrophage cDNA 
clones. It is composed of 69 amino acid residues 
and has been termed MDC because it appears to be 
synthesized specifically by cells of macrophage 
lineage.6 Unlike most other CC chemokines, MDC 
is clustered on chromosome 16q13. It was 
previously known as STCP-1 (stimulated T cell 
chemotactic protein-1). It has the 4 cysteine motif 
and other highly conserved residues characteristic 
of CC chemokines, but it shares less than 35% 
sequence identity with other human chemokines, 
especially TARC being its closest known human 
relative.7, 8  
CCR4/MDC axis plays an important role in the 
long-term recruitment of TH2 cells into the 
inflammatory sites and the regulation of TH2-
related immune responses. CCR4/MDC axis has 
been directly associated with an asthma diagnosis 
and found to be inversely related to lung function as 
measured by FEV1.9 The established in vivo 
significance of distinct CCR4 expression on TH2 
cells, and chemotactic and activating effects of 
MDC on TH2 cells and the association of TH2 cells 
with asthma activity and severity suggest that this 
axis is pivotal in asthma.10 The current study is 
therefore aimed to elucidate the role of CCR4/MDC 
axis in pediatric asthma by tracing and following up 
their expression during activity and in-between 
attacks and to outline their relation to other 
parameters denoting disease activity, degree of 
severity, and response to therapy. Also, to evaluate 
their discriminative value between allergic asthma 
and infection-associated bronchospasm. This may 
have an implication for new non-conventional lines 
of therapy.  
   
METHODS 
This follow-up, case-control study was conducted 
over a period of 1 year from March 2004 to the end 
of February 2005. It comprised 64 children divided 
into 3 main groups: 32 children with allergic 
bronchial asthma (group I), 12 children with acute 
lower respiratory tract infections (group II), and 20 
healthy children not expressing airway disease 
(group III) serving as controls An informed consent 
was obtained from the parents or caregivers of each 
child before enrollment. 
Group (I): It comprised 32 children enrolled from 
the Pediatric Allergy and Immunology Unit of Ain 
Shams University Children’s Hospital while 
presenting with an acute asthmatic exacerbation. 
They were followed-up until complete clinical 
subsidence of the attack and then re-evaluated. 
Their ages ranged between 3 and 12 years (mean ± 
SD = 7.6 ± 2.3 years), and they comprised 20 boys 
(62.5%) and 12 (37.5%) girls. The asthma 
exacerbations were triggered by exposure to 
allergens (food, animal allergens or both) in 20 
children and upper respiratory tract infections in 3 
children. In 9 children, the triggering agent was not 
clear. Thirteen children (41%) presented with acute 
severe asthma, 9 (28%) with moderate severe 
asthma, and 10 (31%) had exacerbations of mild 
severity based on clinical data and peak expiratory 
flowmetry (PEFR).11, 12 Sixteen patients (50%) had 
radiological evidence of hyperinflation and 
increased bronchovascular markings. Based on the 
criteria of asthma grading, the clinical severity of 
the recruited asthmatics during stability were 
classified into intermittent asthma (IA) in 17 
children (53%) and persistent asthma (PA) in 15 
children (47%) according to the Global Initiative 
for Asthma (GINA) guidelines.13 Asthmatic 
children were further subdivided according to 
intake of inhaled corticosteroids into those on 
therapy (n=14; 44%) (mean dose = 250 ± 50µg and 
a mean duration of 8.2 ± 6.4 months and those who 
were not (n=18; 56%). The latter group was on one 
or more of the following medications: inhaled 
sodium cromoglycate, oral/inhaled β2 agonists, or 
theophylline. 
Group (II): It comprised 6 boys and 6 girls whose 
ages ranged from 4 to 11 years with a mean ± SD of 
7 ± 1.4 years. They were enrolled after exclusion of 
a past, current or family history of allergic 
disorders, peripheral blood eosinophilia or elevated 
serum total IgE for age.14 Detailed history taking, 
clinical examination, and chest auscultation 
findings as well as chest radiographs were 
consistent with the diagnosis of bronchopneumonia 
in 4 patients, lobar pneumonia in 3 patients, 
bronchiectasis in 3 patients (secondary to cystic 
fibrosis), and chronic bronchitis in 2 patients. 
Children with bronchiectasis and chronic bronchitis 
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were sampled during an acute exacerbation of 
infection. 
Group (III): It comprised 11 boys (55%) and 9 
girls (45%) whose ages ranged from 5 to 12 years 
with a mean ± SD of 8 ± 2.2 years. They were 
enrolled after exclusion of a personal and family 
history of allergic disorders, peripheral blood 
eosinophilia or elevated serum total IgE for age.14 
Patients or control subjects with clinical or 
laboratory evidence of any parasitic or other 
concomitant illness were excluded from the study. 
We also excluded children with weights and/or 
heights below the 5th percentiles for age.15  
 
Study Design 
Blood samples from group (I) were collected within 
24 hours of the start of an asthma exacerbation 
defined by increasing cough, wheezing, dyspnea 
and nocturnal symptoms. Patients received a 
reliever medication in the form of a β2 agonist by 
nebulizer, and if necessary, oral or intravenous 
steroids and oxygen. After subsidence of the 
episode, the patients were returned to the controller 
medications. Follow up was carried out for 2 to 3 
weeks until stabilization of the patients' condition 
and quiescence of symptoms (remission or steady 
state), then a follow up blood samples were 
collected for re-assessment. By that time, none of 
the asthmatics had evidence of pulmonary 
infections (clinical or radiological and confirmed by 
a normal total leukocyte count). 
 
Analytical Methods  
Blood sampling 
Six ml of venous blood were collected under 
complete aseptic precautions and were divided into 
3 equal parts. Two of them were mixed with EDTA 
as an anticoagulant; one for blood counting and 
flow cytometric analysis, and the other for plasma 
MDC assay, and a third was not added to any 
anticoagulant. After coagulation, the latter sample 
was centrifugated for 15 minutes at 1500 x g. The 
separated serum was stored at -70°C for the 
subsequent assay of total IgE. Repeated thawing 
and freezing was avoided. Hemolyzed and lipemic 
samples were excluded.  
 
MDC/CCL22 assay 
MDC was determined by a quantitative sandwich 
enzyme immunoassay technique using reagents 
supplied by Quantikine (R&D Systems, Inc. 
McKinley Place N.E., Minneapolis, Minnesota, MN 
55413 U.S.A.). A monoclonal antibody specific for 
MDC had been pre-coated onto a microplate. 
Standards and samples were pipetted into the wells 
and any MDC present was bound by the 
immobilized antibody. After washing away any 
unbound substances, a horseradish peroxidase-
linked monoclonal antibody specific for MDC was 
added to the wells. Following a wash to remove any 
unbound antibody-enzyme reagent, a substrate 
solution of hydrogen peroxide-tetramethylbenzidine 
was added to the wells and color developed in 
proportion to the amount of MDC bound in the 
initial step. The color development was stopped by 
2N sulfuric acid and the intensity of the color was 
measured at 450 nm and 540 nm. Readings at 540 
nm were subtracted. For calculation of results, a 
standard curve was constructed on a log/log scale 
by plotting the mean absorbance for each standard 
on the y-axis against the concentration on the x-axis 
and drawing a best fit curve through the points on 
the graph.  
 
Flow cytometric assay of CCR4 on peripheral 
blood T lymphocytes 
The assay was performed on peripheral blood cells. 
The total leukocytic count in EDTA anticoagulated 
whole blood samples was adjusted to 5-10 X 103 
cell/µl and 100 µl of each sample were added to a 
tube containing 10 µl of the monoclonal antibodies 
under study. Contaminating serum components 
were removed by washing the cells three times in 
an isotonic phosphate buffer (supplemented with 
0.5% BSA) by centrifugation at 500 x g for 5 
minutes. 50 µl of packed cells were then transferred 
to a 5 ml tube for staining with monoclonal 
antibodies. Labeled antibodies with fluorescein 
isothiocyanate (FITC), and phycocyanine 5 (PC5) 
in optimal dilutions were used (Becton-Dickinson, 
CA, USA). The studied antibodies included CD3-
PC5, and CCR4-FITC. Negative isotype matched 
controls (FITC and PC5 labeled) were used to 
determine the nonspecific binding of monoclonal 
antibodies.CCR4 assay was performed using 
Coulter EPICS XL flow cytometer (Coulter 
Electronics, USA). CCR4 monoclonal antibodies 
(monoclonal anti-human CCR4-Fluorescein FITC, 
Catalog Number: FAB1567F), was purchased from 
R&D Systems, Inc. McKinley Place N.E., 
Minneapolis Minnesota, MN, USA. Assays were 
performed to quantitatively determine the 
percentage of T cells bearing CCR4 and 
qualitatively determine the density of CCR4 on cell 
surfaces by flow cytometry. Washed cells were 
incubated with the fluorescein-labeled monoclonal 
antibody that binds to the cells expressing human 
CCR4. Unbound fluorescein-conjugated antibody 
was then washed from the cells. Cells expressing 
CCR4 were fluorescently stained, with the intensity 
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of staining directly proportional to the density of 
CCR4. Cell surface expression of CCR4 was 
determined by flow cytometric analysis using 
488nm wavelength laser excitation. T lymphocytes 
were electronically gated using CD3-PC5. Results 
were expressed as percentage of cells co-expressing 
the predetermined markers in comparison to isotype 
matched controls.  
 
Serum total IgE 
Serum total IgE was assayed in all subjects by 
quantitative enzyme immunoassay (Medix Biotech, 
San Carios, CA, USA). Results were expressed in 
IU/ml. Owing to the variability in serum total IgE 
levels with age in childhood, we calculated the 
percentage values from the reference ranges by 
dividing the subject’s actual level by the highest 
normal for age multiplied by 100.14 IgE levels used 
in the correlations were both the measured and the 
calculated percentage values. The serum total IgE 
level that exceeded the highest normal for age was 
considered elevated.   
 
Complete blood count 
The blood count was performed in every subject 
with the Coulter counter (Coulter MicroDiff 18, 
Fullerton CA, USA). The differential leukocytic 
counts were estimated manually form the blood 
film and expressed in absolute count values. Infants 
and children whose absolute eosinophil counts 
(AEC) exceeded the normal reference values for 
age14 were considered to have peripheral blood 
eosinophilia. Blood sampling of all subjects was 
performed at the same time (10 am) daily to avoid 
diurnal variations in eosinophil counts. 
 
Statistical Analysis 
All statistical analyses were carried out using SPSS 
(Statistical Package for the Social Science) version 
9.02 for Windows system. Data were expressed as 
mean, standard deviation (SD), median, and 
interquartile range (IQR) (ranges between 25th-75th 
percentiles). Student's "t" test was used for 
comparing parametric data between two groups. For 
non-parametric comparison of plasma MDC and 
PBTL cells % bearing CCR4 among different 
groups, we used Mann-Whitney U test. The relation 
between the various numerical parameters was 
studied by the Pearson correlation coefficient (r) 
test with graphic representation using linear 
regression line, r value was considered weak if 
<0.5, moderate if ranged between 0.5-0.75 and 




Plasma MDC levels and CCR4+PBTL % in the 
studied groups (table1): 
Plasma MDC levels during acute attacks of 
bronchial asthma ranged between 420 and 1850 
pg/ml (median = 1050, mean ± SD = 925 ± 471.5 
pg/ml). After subsidence of acute attacks, there was 
a significant decrease in MDC levels which ranged 
from 200 to 890 pg/ml and the median and mean ± 
SD values were 506 and 502 ± 284.3 pg/ml 
respectively (Z = 2.8; p<0.0001). The healthy 
children had much lower plasma levels (range = 70-
182, median = 101, mean ± SD = 99.6 ± 25.6 
pg/ml) as compared to the patients’ data whether 
during asthma exacerbation (Z = 4.3; p<0.0001) or 
quiescence (Z = 3.6; p<0.0001). 
CCR4+PBLT % values of asthmatic patients 
during acute exacerbations ranged between 50 and 
90% (median = 65, mean ± SD = 55.3 ± 23.6%). 
After subsidence of acute attacks, there was a 
significant decrease in CCR4% ranging from 22 to 
60% and the median and mean ± SD levels were 35 
and 32.5 ± 10.5% respectively (Z = 2.1; p<0.0001). 
Healthy controls had significantly lower % (range = 
20-30, median = 25, mean ± SD = 24.2 ± 4.1%) as 
compared to the patients’ data both during 
exacerbations (Z = 2.4; p<0.0001), and quiescence 
(Z = 1.6; p<0.05).  
Plasma MDC levels of children with acute 
lower respiratory tract infections ranged from 80 up 
to 209 pg/ml (median = 115, mean ± SD = 109 ± 
27.3 pg/ml). Their CCR4+PBTL% ranged between 
20-35% (median = 27, mean ± SD = 27.6 ± 7.5%).  
These values were significantly lower as compared 
to the values of children with atopic asthma 
whether during exacerbations (Z = 3.8; p<0.0001 
for MDC; and Z = 1.9; p<0.05 for CCR4+PBTL%), 
or during quiescence (Z = 3.2; for MDC; and 1.1 
for CCR4+PBTL%, p<0.05 for both). On the other 
hand, they were statistically comparable to the 
values of controls (p>0.05 for both markers).  
 
Plasma MDC levels and CCR4+PBTL% in relation 
to severity of acute asthma exacerbations, and 
asthma grading during stability (figure 1): 
Plasma MDC levels and CCR4+PBTL% values 
were significantly higher in children enrolled with 
acute severe asthma as compared to those with mild 
attacks or those with moderate exacerbations. Also, 
children with moderate attacks had significantly 
higher levels than those with mild attacks (fig.1). 
Concerning asthma grading, during stability, 
patients with persistent asthma (mild, moderate and 
severe persistent) had significantly higher plasma 
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MDC levels (median = 400; mean ± SD = 325 ± 
252 pg/ml) and higher CCR4+PBTL% (median = 
30; mean ± SD = 30 ± 27 %) as compared to 
intermittent asthma (median = 235; mean ± SD = 
223 ± 265 pg/ml for MDC; median = 25; mean ± 
SD = 22 ± 21% for CCR4%). Again, higher levels 
were observed when data of patients with persistent 
asthma were compared to controls (p<0.05 for both 
markers).  
 
CCR4/MDC axis in relation to asthma clinical, 
laboratory and radiological variables and response 
to inhaled steroid therapy (table2; figure 2, 3 &4):  
There were significant positive correlations 
between plasma MDC levels and CCR4+PBTL% 
both during exacerbations (fig.2A), and during 
quiescence (fig.2B). Plasma MDC levels during 
acute exacerbations were positively correlated with 
the corresponding values after remission meaning 
that the higher the levels got during attacks the 
higher they remained after remission (fig.3A). A 
similar correlation was found in terms of 
CCR4+PBTL% (fig.3B). Significant negative 
correlations were reported between PEFR during 
acute asthmatic attacks and plasma MDC levels (r=-
0.51; p<0.05) and CCR4+PBTL% (r=-0.55; 
p<0.05). In quiescence, such correlations were 
absent (p>0.05 for both markers). There were 
significant positive correlations between the 
absolute eosinophil count during acute asthmatic 
attacks and plasma MDC levels and CCR4+PBTL% 
(fig.4). In quiescence, such correlations were absent 
(p>0.05 for both markers). The plasma MDC levels 
and CCR4+PBTL% could not be related by 
correlation coefficient to age, weight centiles, 
height centiles, IgE concentrations or IgE percent 
values from normal during or after subsidence of 
asthma exacerbation. Both, markers were not 
influenced by age, gender, or family history.  
The plasma MDC levels in-between asthmatic 
attacks were significantly higher in children who 
demonstrated X-ray findings of hyperinflation and 
increased bronchovascular markings than in 
patients with normal chest X-ray (median = 610;  
mean ± SD = 559 ± 410 pg/ml versus 450 and 410 
± 313 pg/ml; p<0.05). However, the same did not 
apply when studied during acute exacerbations 
(median = 1000 versus 950 pg/ml, p>0.05). 
Concerning CCR4+PBTL%, the results were not 
influenced by the presence of radiological findings 
whether in activity or remission.  
Plasma MDC levels and CCR4+PBTL% 
expression did vary according to the corticosteroid 
inhalation therapy, being significantly higher in 
steroid-treated patients both during exacerbation or 
quiescence (table 2). 
 
Table 1. Plasma macrophage-derived chemokine (MDC/CCL22) and 
the percentage of peripheral blood T lymphocytes expressing the CC 
chemokine receptor-4 (CCR4) in the studied groups  
 






Acute attacks In-between 
Plasma MDC/CCL22 (pg/ml) 
Range 420-1850 200-890 80-209 70-182 
Median 1050 506 115 101 
Mean ± SD 925 ± 471.5 502 ± 284.3 109 ± 27.3 99.6 ± 25.6 
Z1 2.8 **   
Z2 3.8 ** 3.2 *   
Z3 4.3 ** 3.6 ** 0.9 #  
CCR4+PBTL (%) 
Range 50-90 22-60 20-35 20-30 
Median 65 35 27 25 
Mean ± SD 55.3 ± 23.6 32.5 ± 10.5 27.6 ± 7.5 24.2 ± 4.1 
Z1 2.1 **   
Z2 1.9 * 1.1 *   
Z3 2.4 ** 1.6 * 0.5 #  
ALRTI: acute lower respiratory tract infections; CCR4: CC receptor-4; MDC: 
macrophage-derived chemokine; PBTL: peripheral blood T lymphocytes 
Mann-Whitney test was employed, Z1: acute asthmatic attacks versus stability; Z2: 
asthma versus ALRTI; Z3: patients (asthma or ALRTI) versus controls 
*: Significant (p<0.05), **: Highly significant (p<0.0001), #: Non-significant (p>0.05). 
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Figure 1. Box-plot summary of plasma macrophage-derived chemokine (MDC) levels (fig.1A) and the % of 
peripheral blood T lymphocytes expressing CCR4 (fig.1B) in relation to the degree of severity of acute 
asthmatic attacks. Mann–Whitney test was used in the comparisons. Black squares represent the median and the 
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Table 2. Variations of plasma macrophage-derived chemokine (MDC/CCL22) 
levels and the percentage of peripheral blood T lymphocytes expressing the CC 
chemokine receptor-4 (CCR4) according to corticosteroid inhalation therapy 
 
 
+ve Steroid  
therapy  
(n = 14) 
-ve Steroid  
therapy  
(n = 18) 
Z  
value p 
Plasma MDC (pg/ml) 
(median; mean ± SD)     
During exacerbation 1320;  1200 ± 618 700;  650 ± 236 2.6 p<0.0001** 
After remission 605;  555 ± 297 410; 449 ± 258 1.3 p < 0.05* 
CCR4+PBTL (%)  
(median; mean ± SD)     
During exacerbation 74;  63 ± 29.5 56;  50 ± 30.2 1.2 p< 0.05* 
After remission 47;  32 ± 22.9 35;  33 ± 23.1 0.97 p < 0.05* 
CCR4: CC receptor-4; MDC: macrophage-derived chemokine; PBTL: peripheral blood T lymphocytes 
Mann-Whitney test was employed 
*: Significant (P<0.05), **: Highly significant (P<0.0001) 
 
















Fig. 2A (Acute attacks)  
















Fig. 2B (In-between attacks)  
 
Figure 2. Positive correlations between the percentage of peripheral blood T lymphocytes expressing the 
chemokine CC receptor-4 (CCR4) and plasma levels of macrophage derived chemokine (MDC) among 
asthmatic children during acute attacks (Fig.2A) and after resolution (Fig.2B). 
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Figure 3. Positive correlations between the plasma levels of macrophage derived chemokine (MDC) (Fig.3A) 
and the percentage of CCR4 bearing T cells (Fig.3B) during and in-between asthma attacks. 
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Fig. 4A  































Figure 4. Positive correlations between the absolute eosinophil count (cells/mm3) and plasma levels of 
macrophage derived chemokine (MDC) (Fig.4A), and the percentage of CCR4 bearing T cells (Fig.4B) among 
asthmatic children during exacerbations. 
 
DISCUSSION 
The critical influence of chemokine biology on the 
outcome of asthma continues to be highlighted in 
recent reports describing novel mechanisms by 
which inflammatory cells are recruited into the 
lungs and the local TH2-cell dominance is 
maintained. Of considerable interest, is the 
increasing emphasis currently being realized for 
receptor mechanisms. In vitro, polarized human 
TH2 cells preferentially express the chemokine 
receptor CCR4, and migrate to its ligand MDC.16 
Therefore; we were stimulated to elucidate the role 
of CCR4/MDC axis in a group of asthmatic 
children. 
During acute asthma attacks, plasma MDC 
levels and CCR4+PBTL% were significantly higher 
in comparison to the corresponding values in the 
stable state and in comparison to controls. These 
data conform with several other reports.17-21 The 
results during exacerbations may reflect the 
upregulation of CCR4 and its ligand, MDC, in 
allergic inflammation, presenting potentially useful 
markers for the presence of atopic response. This 
was also observed in the sera and the lesional skin 
(keratinocytes) of atopic dermatitis and in animal 
models of allergy.4, 7, 21-23 When we followed-up our 
asthmatics to stability, we observed sustained 
elevation of both markers in comparison to control 
values. This might reflect the ongoing inflammatory 
process with persistent infiltration of airways by 
inflammatory cells. These cells release mediators 
that in turn recruit more and more inflammatory 
cells in a vicious circle manner. Such observations 
could be indicative of the continued exposure to 
triggering factors and/or the need for more intensive 
anti-inflammatory treatment. We, therefore, suggest 
that MDC levels and CCR4% be used as markers of 
the ongoing airway inflammatory activity in terms 
of duration. Our results highlight the in vivo 
significance of distinct CCR4 expression on TH2 
cells and CCR4/MDC axis in the setting of chronic 
inflammation and dendritic cells and lymphocytes 
homing in asthma. 
Our data, however, contradict the report of 
Sekiya et al24. Also, the plasma MDC levels in 
acute and stable asthma in the study of Leung et 
al17. were somewhat lower than our levels. This 
may probably reflect the presence of cases of acute 
severe asthma among our studied sample. We found 
very few published data on normal or pathological 
MDC levels in plasma or other biological fluids of 
infants and children. Moreover, MDC studies 
previously identified in the available databases 
were conducted in the bronchoalveolar lavage fluid, 
and exhaled breath condensate among adult 
asthmatics which made the comparison of the 
results somewhat difficult, especially that some 
authors25 reported that MDC studies in vitro and in 
biological fluids cannot simply be extrapolated to 
normal human airway cells.  
We sought to measure MDC in plasma because 
it is easier, rapid and less invasive and would still 
partially reflect the extent of local production by the 
large bronchial epithelial cells that leads to systemic 
expression via pooling in the plasma. This is 
expected to operate in the absence of other allergic 
diseases that might alter MDC levels. 
The cellular source of MDC production has 
been a subject of debate. A number of sources had 
been identified, including macrophages, monocyte-
derived dendritic cells (almost exclusively in the 
thymus), natural killer (NK) cells, and bronchial 
MDC (CCL22) / CCR4 axis in asthma 
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epithelial cells. MDC mRNA was highly identified 
and expressed particularly upon stimulation with 
microbial products, or anti-CD40 antibody. High 
expression was detected in normal thymus 
(medullary epithelial cells) compared to lesser 
expression in the spleen.26, 27 
Human airway epithelial cells were found to 
release MDC upon cytokine stimulation.21 
Immunofluorescent analysis of endobronchial 
biopsies from asthmatics, taken 24 hours after 
allergen challenge, demonstrates that virtually all T 
cells express CCR4.20 Expression of the CCR4-
ligand, MDC, is strongly upregulated on airway 
epithelial cells upon allergen challenge, suggesting 
a major involvement of this receptor/ligand axis in 
TH2-dominated allergen-induced asthma by the 
regulation of lymphocyte recruitment into the 
asthmatic bronchi. Recently, it was found that MDC 
induces concentration-dependent platelet 
aggregation (dependent on cyclooxygenase 
metabolites of arachidonic acid). Flow cytometric 
analysis revealed the expression of CCR4 on 
platelets and a monoclonal antibody to CCR4 
inhibited MDC-induced platelet aggregation, 
confirming that this effect is mediated through its 
receptor CCR4. MDC-production is also 
upregulated by prostaglandin and cyclic AMP-
elevating agents.28 Therefore, CCR4/MDC axis 
may contribute to platelets involvement in TH2-
type inflammation, which certainly deserves intense 
studies.  
MDC chemotactic activity is dose-dependent. 
At low concentrations (1 ng/mL), MDC is 
chemoattractant for monocyte-derived dendritic 
cells, IL-2-activated NK cells and activated T 
lymphocytes. Monocytes and a subpopulation of 
thymocytes migrate in response to much higher 
concentrations of MDC (peak response at 100 
ng/mL). Thus, in vivo production of MDC may first 
attract dendritic cells or NK cells, and further 
accumulation of MDC may cause a subsequent 
influx of monocytes.29 
The positive correlation between plasma MDC 
levels and CCR4% during exacerbations probably 
reflect excessive MDC production from bronchial 
epithelial cells during bursts of bronchial asthma. 
The current finding of positive correlations between 
plasma MDC levels and CCR4% during 
exacerbation and their levels after remission means 
that the higher they get during attacks the higher 
they remain after remission. This may reflect the 
non-stop allergic inflammation inside the airways 
of children mediated by inflammatory cells 
particularly lymphocytes even after subsidence of 
exacerbations. Our conclusion can be ascertained 
also by the presence of a positive correlation 
between the plasma MDC levels and CCR4% 
during stability.  
The concurrent acute lower respiratory tract 
infections in asthma are sometimes impossible to 
distinguish from spontaneous acute exacerbations. 
The question of whether or not the presence of 
airway infection in asthma would increase the 
expression of both markers was one of our 
concerns. Also, cough as a frequent respiratory 
symptom in children, is sometimes difficult to be 
diagnosed as being cough variant asthma. 
Therefore, we investigated whether analysis of 
these markers could facilitate the diagnostic 
discrimination of atopic asthma from infection-
associated airway reactivity and other causes of 
spasmodic cough in children. We therefore, 
included 12 patients with acute lower respiratory 
tract infections in whom the diagnosis of atopic 
asthma was ruled out by medical history, chest 
auscultation and radiographic findings. Among 
these patients, the levels of both markers were 
statistically comparable to healthy controls and 
lower than levels of asthmatic children whether 
during exacerbation or stability. Our findings were 
concordant with some other relevant studies.30, 31 In 
view of these findings, it seems that CCR4/MDC 
axis activation is an inherent feature of atopy and 
that pathogen-induced inflammation in respiratory 
infections is independent on such axis. Both 
markers are thus expected to differentiate asthmatic 
children from those with spasmodic cough due to 
non-allergic causes. Our results are limited by the 
small number of children with infections, thus we 
recommend wider scale studies to verify the results.  
MDC has been suggested as a useful objective 
marker for disease severity in asthma. We have 
demonstrated that MDC plasma levels and 
CCR4+PBTL% correlated with severity of acute 
asthma exacerbations (both parameters were 
significantly higher in children with acute severe 
asthma than in subjects with acute attacks of mild 
or moderate severity). Also, higher levels were 
reported in moderate attacks as compared to mild 
attacks. Similarly, CCR4% and MDC levels were 
reported to be inversely correlated with PEFR. 
Similar results were reported by Leung et al17. and 
Lezcano-Meza et al20. Our results may probably 
reflect excessive influx of inflammatory cells in 
acute severe attacks producing injury to bronchial 
mucosa mediating bronchospasm, bronchial 
obstruction and irritability. It seems that 
CCR4/MDC axis over expression is in favor of an 
asthma diagnosis and impaired lung function and is 
related to asthma severity.  
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Concerning asthma grading in-between attacks, 
CCR4% and MDC levels were significantly higher 
in persistent than intermittent asthma and control 
values. Our data conform with the results of van 
den Toorn et al32. This could be due to the ongoing 
process of sub-clinical allergic inflammation in the 
lungs of persistent asthmatics during clinical 
remission meaning that airway inflammation is still 
present in patients with seemingly stable conditions. 
Our results signify the role of CCR4/MDC axis in 
the persistence and long-term recruitment of TH2 
cells, into the inflammatory sites, setting chronic 
inflammation, and lymphocyte homing. Thus, 
CCR4% and MDC levels might be useful indices in 
determining the magnitude of persistent airway 
inflammation.  
Significant positive correlations could be 
elicited between CCR4% and MDC concentrations 
and the absolute eosinophil counts during acute 
attacks. It was previously mentioned that MDC may 
have a role in regulating the constitutive numbers of 
eosinophils in peripheral blood by inducing 
eosinophil chemotaxis in a CCR3 and CCR4-
independent manner.6, 33 This conforms with our 
data and may signify the role of CCR4/MDC axis in 
the late allergic response. Moreover, such 
correlations highlight two important questions that 
deserve further studies; first: the possibility of 
eosinophil chemotaxis in a CCR4-dependant 
manner, second: whether the effect of MDC on 
eosinophils could be mediated at the level of bone 
marrow where eosinophil growth and development 
has been found predominantly dependent on 
specific chemokines e.g. eotaxin. This may pave 
way for targeting eosinophils in allergic diseases by 
manipulating CCR4/MDC axis. 
In the current study, MDC levels and CCR4% 
could not be correlated to the serum total IgE 
concentrations or % values from normal either 
during or after subsidence of exacerbations. 
However, the number of cases in the normal IgE 
category was too small to come out with a 
conclusion. It may also reflect varying mechanisms 
regulating their actions. 
Plasma MDC levels during stability were 
significantly higher in children who demonstrated 
X-ray findings of hyperinflation and increased 
bronchovascular markings than in patients with 
normal X-rays. This may enforce the relation 
between MDC expression and asthma chronicity 
and severity as reflected by the radiological 
findings. The same, however, did not apply during 
asthma exacerbations. Also, the absence of such 
correlation in terms of CCR4% values would limit 
the significance of the aforementioned conclusion. 
Otherwise, such observation would have been better 
outlined with a larger sample size. 
The effect of inhaled corticosteroid therapy on 
CCR4/MDC axis was highly impressive. We had 
observed significant higher levels of both markers 
in steroid-treated patients during and in-between 
attacks. This was contradictory to the reports of 
Leung et al17. who found that MDC concentrations 
in exhaled breath condensate were lower in patients 
with persistent asthma who received high-dose 
inhaled corticosteroids. The studied material is 
different in our series and this may account for the 
difference. Our finding might also be explained by 
the fact that severe cases received higher steroid 
doses and that their overexpression of the studied 
markers actually reflected the effect of severity 
rather than therapy. It is possible that in some 
asthmatic subjects, steroids do not inhibit the robust 
expression of MDC or its receptor CCR4. Although 
it was previously noted that glucocorticoids could 
inhibit the in vitro expression of many chemokines 
including MDC, the results of studies that used 
bronchial cell lines and mouse models may not 
apply to in vivo expression of this chemokine. This 
may lead to the speculation that therapeutic 
strategies aimed at blocking the effects of MDC by 
inhibiting its receptor (CCR4) might benefit some 
symptomatic, corticosteroid-dependent, asthmatic 
subjects. 
In conclusion, plasma MDC levels and CCR4 
expression on peripheral blood T lymphocytes were 
up regulated. They are expected to have biological 
significance in the regulation of lymphocyte 
recruitment into the asthmatic bronchi leading to 
development of the pathophysiological endpoint of 
asthma, the airway hyperreactivity. CCR4/MDC 
axis changes were not only related to asthma 
activity but to asthma severity as well. Also, the 
axis seems to be involved in the establishment and 
maintenance of chronic inflammation of the 
airways. CCR4 and its ligand MDC might be useful 
markers for monitoring allergic inflammation in 
asthma, and might be useful in differentiating 
atopic asthma from non allergic respiratory 
symptoms and infections-associated airway 
reactivity. Setting pediatric reference ranges for 
MDC in biological fluids, and exploring CCR4 
expression on different immune cells involved in 
atopy are worthwhile. Moreover, the effect of MDC 
and CCR4 antagonists and other 
immunotherapeutics, like monoclonal antibodies on 
the MDC kinetics and CCR4 expression deserves 
intense evaluation. CCR4/MDC antagonism may 
prove value one day as a potential adjuvant 
therapeutic strategy in bronchial asthma. 
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